Roflumilast Versus Methotrexate in Psoriasis

• Status: Not yet recruiting
• Trial end date: 2023-04-15
• Target enrollment: 0
• Participant gender: All

Summary

Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which is approved in its oral form for chronic obstructive pulmonary disease, and in its topical form in the treatment of plaque psoriasis. Methotrexate is one of the conventional systemic treatments of psoriasis, so the aim of this study is to compare the efficacy and safety of roflumilast and methotrexate in the treatment of psoriasis

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

1. Patients with psoriasis vulgaris

2. Psoriatic patients not receiving any relevant systemic treatment for at least 4 weeks before initiation of our study

3. Psoriatic patients not receiving any relevant topical treatment for at least 2 weeks before initiation of our study

Exclusion Criteria:

1. Erythrodermic or pustular psoriasis

2. Pregnant and lactating females

3. Patients with autoimmune diseases e.g. systemic lupus erythematosus

4. Patients with solid or hematological malignancies e.g., breast cancer, leukemia, etc.